Madduri Srinivasarao

Dr. Madduri's lab pioneers ligand-directed therapeutic strategies that precisely deliver cytotoxic payloads to defined cell populations, leveraging cell-specific targeting ligands to maximize efficacy while minimizing off-target toxicity. As a highly interdisciplinary team, they engineer innovative treatments spanning cancer, autoimmune disorders, fibrosis, metabolic diseases, and rare conditions. Their portfolio includes the development of radioligand therapies, next-generation immunotherapies, and engineered cell-based platforms. Through active partnerships with pharmaceutical collaborators, his group drives the translation of discoveries from bench to bedside.